Shots:

• Seattle Genetics and Astellas sign a clinical trial agreement with Merck to evaluate the combination of Seattle Genetics’ and Astellas’ ADC and Merck’s anti-PD-1 therapy in patients with previously untreated metastatic urothelial cancer
• The three companies will conduct and fund P-III study to be led by Seattle Genetics and will work with regulatory authorities to finalize the trial design with the expected onset of the study in H1’20
• Enfortumab Vedotin is an investigational ADC comprising of an anti-Nectin-4 mAb- attached to a MMAE utilizing Seattle Genetics' technology and has received FDA’s BT designation in Mar’2018 with its PDUFA date as Mar 15- 2020

Click here to­ read full press release/ article 

Ref: Astellas | Image: Merck